Web Exclusives

Preliminary results from the ongoing ALPINE study suggest that zanubrutinib may have superior efficacy and an improved safety profile compared with ibrutinib in previously treated patients with chronic lymphocytic leukemia.

Results from the 4-year follow-up of the ELEVATE-TN study support acalabrutinib with or without immunotherapy in previously untreated patients with chronic lymphocytic leukemia.

Being diagnosed with cancer and undergoing subsequent treatment can be challenging for patients and their partners, but intimacy does not have to end.

Patients with cancer can take a proactive role in their overall well-being by finding out what types of activities work best for them to combat feelings of isolation.

As we recognize National Immunization Awareness Month, let’s focus on building awareness of the latest vaccination guidance and requirements to support parents of children and teens with pediatric cancer.

Cancer treatment is complicated; an oncology patient advocate can help uncomplicate the journey by advocating and being a voice for their patients with cancer.

Ongoing clinical trials are poised to expand the role of acalabrutinib in treating chronic lymphocytic leukemia.